Laboratory monitoring analysis and prospects for using its results in specialized clinical diagnostic laboratory-Reference-Cited by-同舟云学术

Laboratory monitoring analysis and prospects for using its results in specialized clinical diagnostic laboratory

Published:2020-06-15 Issue:5 Volume: Page:8-12
ISSN:2078-5631
Container-title:Medical alphabet
language:
Short-container-title:Medicinskij alfavit

Author:

Bibikova V. V.¹,Emanuel V. L.¹

Affiliation:

1. First Saint Petersburg State Medical University n. a. I. P. Pavlov

Abstract

This article presents a retrospective analysis of the laboratory monitoring orders from the specialized clinical laboratory. It has been established that large amounts of information about rare, poorly understood diseases and special types of pathology are accumulated during the everyday activity of specialized clinical laboratory. This research indicated that the share of laboratory monitoring, with 17 % of all orders, has a tendency to increase, which may be associated with the improvement of laboratory diagnostic methods. The possibility of laboratory monitoring results using in order to facilitate diagnostic process by the means of an optimal examination algorithm compiling, as well as to study regional pathology, is discussed. Besides, the prospects of using information on laboratory monitoring in improving the organization of specialized clinical laboratory’s activity are assessed.

Publisher

Alfmed LLC

Subject

Materials Chemistry,Economics and Econometrics,Media Technology,Forestry

Reference9 articles.

1. Geerts A., De Koning F., Van Solinge W., De Smet P. and Egberts T. (2012). Instructions on laboratory monitoring in 200 drug labels. Clinical Chemistry and Laboratory Medicine, 50 (8).

2. Giacomelli R, Afeltra A, Alunno A, Baldini C, Bartoloni-Bocci E, Berardicurti O, Carubbi F, Cauli A, Cervera R, Ciccia F, Cipriani P, Conti F, De Vita S, Di Benedetto P, Doria A, Drosos AA, Favalli EG, Gandolfo S, Gatto M, Grembiale RD, Liakouli V, Lories R, Lubrano E, Lunardi C, Margiotta DPE, Massaro L, Meroni P, Minniti A, Navarini L, Pendolino M, Perosa F, Pers JO, Prete M, Priori R, Puppo F, Quartuccio L, Ruffatti A, Ruscitti P, Russo B, Sarzi-Puttini P, Shoenfeld Y, Somarakis GA, Spinelli FR, Tinazzi E, Triolo G, Ursini F, Valentini G, Valesini G, Vettori S, Vitali C, Tzioufas AG. International consensus: What else can we do to improve diagnosis and therapeutic strategies in patients affected by autoimmune rheumatic diseases (rheumatoid arthritis, spondyloarthritides, systemic sclerosis, systemic lupus erythematosus, antiphospholipid syndrome and Sjogren’s syndrome)?: The unmet needs and the clinical grey zone in autoimmune disease management. Autoimmun Rev. 2017 Sep; 16 (9): 911–924.

3. Raebel M, Lyons E, Andrade S et al. Laboratory monitoring of drugs at initiation of therapy in ambulatory care. J Gen Intern Med. 2005; 20 (12): 1120–1126. DOI: 10.1111/j.1525–1497.2005.0257.x.

4. Rigby W., Lampl K., Low J. and Furst D. (2017). Review of Routine Laboratory Monitoring for Patients with Rheumatoid Arthritis Receiving Biologic or Nonbiologic DMARDs. International Journal of Rheumatology, 2017, pp. 1–15.

5. Stephenson D., Hu M., Romero K., Breen K., Burn D., Ben-Shlomo Y., Bhattaram A., Isaac M., Venuto C., Kubota K., Little M., Friend S., Lovestone S., Morris H., Grosset D., Sutherland M., Gallacher J., Williams-Gray C., Bain L., Avilés E., Marek K., Toga A., Stark Y., Forrest Gordon M. and Ford S. (2015). Precompetitive Data Sharing as a Catalyst to Address Unmet Needs in Parkinson’s Disease 1. Journal of Parkinson’s Disease, 5 (3), pp. 581–594.